Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Trends (04/2007): Patient Safety: Where's the Progress?

Executive Summary

Despite the many safety initiatives introduced to the healthcare industry in the last 10 years, the number of patient safety incidents at hospitals are not declining dramatically. In fact, the opposite is true: from 2003 to 2005, patients safety incidents were up almost 3% in U.S. hospitals, and resulted in $8.6 billion in excess hospital costs.

You may also be interested in...



Hospital-Acquired Conditions: Patient Safety Concerns Fuel Device Innovation

New federal initiatives to improve patient safety are taking direct aim at hospitals' bottom line by making them bear the increased costs of treatment when patients acquire a condition deemed reasonably preventable. At this year's meeting of the Association of Operating Room Nurses, companies showcased new technologies designed to help hospitals avoid so-called "never events" like leaving objects in a patient after surgery, pressure ulcers acquired during a patient's stay, and certain nosocomial infections.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel